<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[license agreement and wyeth Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/license+agreement+and+wyeth.html?i=11]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to license agreement and wyeth]]></description>
	<s:counts start="0" returned="5" found="5" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Mochida, Wyeth Enter License Agreement for Novel Pain Treatment]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_qn6209/is_20080111/ai_n24410195]]></link>
		<description><![CDATA[Tokyo, Jan 11, 2008 - JCN - Mochida Pharmaceutical announced that it has licensed a portfolio of transient receptor potential vanilloid sub type 1 (TRPV1) receptor antagonists - a potential novel treatment for pain - to Wyeth Pharmaceuticals.]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 11 Jan 2008 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/license+agreement.html"><![CDATA[license agreement]]></category>
		<category domain="http://resources.bnet.com/topic/wyeth.html"><![CDATA[Wyeth]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WYE</category>
		<category domain="tickers">WYE</category>
	</item>
	<item>
		<title><![CDATA[Flamel Technologies Announces Medusa® License Agreement with Wyeth Pharmaceuticals]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_Sept_12/ai_n27371102]]></link>
		<description><![CDATA[LYON, France -- Flamel Technologies (Nasdaq:FLML) announced today that it has entered into a development and license agreement with Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE). The agreement is for the development and licensing of a marketed protein to be delivered using Flamel's Medusa technology. Flamel will receive an upfront...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 12 Sep 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/license+agreement.html"><![CDATA[license agreement]]></category>
		<category domain="http://resources.bnet.com/topic/wyeth.html"><![CDATA[Wyeth]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WYE</category>
		<category domain="tickers">WYE</category>
	</item>
	<item>
		<title><![CDATA[Crucell Announces PER.C6(R) and AdVac(R) Technology License Agreement with Wyeth Pharmaceuticals]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200707/ai_n19429168]]></link>
		<description><![CDATA[Leiden, The Netherlands, July 30  2007 - Dutch biotechnology  company Crucell N.V.  (Euronext, NASDAQ:  CRXL,  Swiss Exchange:  CRX)  today announced that it has entered into a co-exclusive PER.C6® and  Advac® technology license agreement with  Wyeth Pharmaceuticals, a  division of Wyeth...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 30 Jul 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/agreement.html"><![CDATA[agreement]]></category>
		<category domain="http://resources.bnet.com/topic/license+agreement.html"><![CDATA[license agreement]]></category>
		<category domain="http://resources.bnet.com/topic/wyeth.html"><![CDATA[Wyeth]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WYE</category>
		<category domain="tickers">WYE</category>
	</item>
	<item>
		<title><![CDATA[Wyeth Renews and Expands License Agreement With Ingenuity Systems.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5570/is_200705/ai_n23620792]]></link>
		<description><![CDATA[REDWOOD CITY, California, May 2 /PRNewswire/ --    REDWOOD CITY, California, May 2 /PRNewswire/ --  ]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 02 May 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/license+agreement.html"><![CDATA[license agreement]]></category>
		<category domain="http://resources.bnet.com/topic/wyeth.html"><![CDATA[Wyeth]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WYE</category>
		<category domain="tickers">WYE</category>
	</item>
	<item>
		<title><![CDATA[Ablynx Enters into a Research and License Agreement with Wyeth]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2006_Nov_6/ai_n16910666]]></link>
		<description><![CDATA[GHENT, Belgium -- Ablynx, the pioneer in the discovery and development of Nanobodies([R]), a novel class of antibody-derived therapeutic proteins, has announced that they have entered into an exclusive research collaboration and license agreement with Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), to discover, develop and commercialise Nanobodies([R]) directed at...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 06 Nov 2006 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/license+agreement.html"><![CDATA[license agreement]]></category>
		<category domain="http://resources.bnet.com/topic/wyeth.html"><![CDATA[Wyeth]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WYE</category>
		<category domain="tickers">WYE</category>
	</item>
</channel>
</rss>
